Study of the relationship between antiemetic effect of aprepitrant and genetic polymorphism of ABC transporter
Not Applicable
Recruiting
- Conditions
- Malignant tumor (lung cancer, gastric cancer, etc)
- Registration Number
- JPRN-UMIN000004910
- Lead Sponsor
- Department of Clinical Pharmacology and Genitics, School of Pharmaceutical Science, Univercity of Shizuoka
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Known prior severe hypersensitivity to platinum-containing drug, 5HT3 receptor antagonist, corticosteroids and aprepitant 2) Patients who do not have enough whole body state to the antineoplastic agents treatment 3) Pregnant, breastfeeding or expecting woman 4) Patient with severe uncontrollable diabetes mellitus 5) Known symptomatic brain metastasis 6) Patients who take a medicine regularly such as corticosteroids, dopamine D2-receptor antagonist, phenothiazine tranquilizers, antihistamine drugs and benzodiazepine etc 7) Other clinical difficulties in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method